Compounds > n,n'-bis(2-pyridylmethylene)-1,4-butanediamine (n,n',n'',n''')-cu(ii)diperchlorate
Page last updated: 2024-09-04

n,n'-bis(2-pyridylmethylene)-1,4-butanediamine (n,n',n'',n''')-cu(ii)diperchlorate and Leukemia, Erythroblastic, Acute

n,n'-bis(2-pyridylmethylene)-1,4-butanediamine (n,n',n'',n''')-cu(ii)diperchlorate has been researched along with Leukemia, Erythroblastic, Acute in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Mavelli, I; Melino, G; Pedersen, JZ; Rossi, L; Rotilio, G; Steinkühler, C; Weser, U1

Other Studies

1 other study(ies) available for n,n'-bis(2-pyridylmethylene)-1,4-butanediamine (n,n',n'',n''')-cu(ii)diperchlorate and Leukemia, Erythroblastic, Acute

ArticleYear
Cytotoxicity of a low molecular weight Cu2Zn2 superoxide dismutase active center analog in human erythroleukemia cells.
    Biochemical pharmacology, 1990, May-01, Volume: 39, Issue:9

    Topics: Binding Sites; Catalase; Drug Screening Assays, Antitumor; Glutathione; Humans; Hydrogen Peroxide; Imidazoles; Leukemia, Erythroblastic, Acute; Lymphocytes; Organometallic Compounds; Oxygen Consumption; Schiff Bases; Superoxide Dismutase; Tumor Cells, Cultured

1990